181 related articles for article (PubMed ID: 20653511)
1. Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding.
Ho L; Pasinetti GM
Expert Rev Proteomics; 2010 Aug; 7(4):579-89. PubMed ID: 20653511
[TBL] [Abstract][Full Text] [Related]
2. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies.
Ho L; Yemul S; Wang J; Pasinetti GM
J Alzheimers Dis; 2009; 16(2):433-9. PubMed ID: 19221432
[TBL] [Abstract][Full Text] [Related]
3. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
Rockenstein E; Crews L; Masliah E
Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
[TBL] [Abstract][Full Text] [Related]
4. Strategies for the inhibition of protein aggregation in human diseases.
Bartolini M; Andrisano V
Chembiochem; 2010 May; 11(8):1018-35. PubMed ID: 20401887
[TBL] [Abstract][Full Text] [Related]
5. Nanoimaging for protein misfolding diseases.
Lyubchenko YL; Kim BH; Krasnoslobodtsev AV; Yu J
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):526-43. PubMed ID: 20665728
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy targeting misfolded proteins in neurodegenerative disease].
Kanemaru K
Brain Nerve; 2013 Apr; 65(4):469-74. PubMed ID: 23568995
[TBL] [Abstract][Full Text] [Related]
7. Bringing natural products into the fold - exploring the therapeutic lead potential of secondary metabolites for the treatment of protein-misfolding-related neurodegenerative diseases.
Joyner PM; Cichewicz RH
Nat Prod Rep; 2011 Jan; 28(1):26-47. PubMed ID: 20927454
[TBL] [Abstract][Full Text] [Related]
8. Visual aspects of neurologic protein misfolding disorders.
Pula JH; Kim J; Nichols J
Curr Opin Ophthalmol; 2009 Nov; 20(6):482-9. PubMed ID: 19816176
[TBL] [Abstract][Full Text] [Related]
9. [Neurodegenerative conformational disease and its molecular bases].
Li WW; Cai DF; Ren HM
Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610
[TBL] [Abstract][Full Text] [Related]
10. Protein misfolding in neurodegenerative diseases.
Agorogiannis EI; Agorogiannis GI; Papadimitriou A; Hadjigeorgiou GM
Neuropathol Appl Neurobiol; 2004 Jun; 30(3):215-24. PubMed ID: 15175075
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic strategies for targeting neurodegenerative protein misfolding disorders.
Scannevin RH
Curr Opin Chem Biol; 2018 Jun; 44():66-74. PubMed ID: 29902695
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins.
Naiki H; Nagai Y
J Biochem; 2009 Dec; 146(6):751-6. PubMed ID: 19643812
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of disease II: cellular protein quality control.
Outeiro TF; Tetzlaff J
Semin Pediatr Neurol; 2007 Mar; 14(1):15-25. PubMed ID: 17331880
[TBL] [Abstract][Full Text] [Related]
14. Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw.
Spires TL; Hannan AJ
FEBS J; 2005 May; 272(10):2347-61. PubMed ID: 15885086
[TBL] [Abstract][Full Text] [Related]
15. Defective protein folding and aggregation as the basis of neurodegenerative diseases: the darker aspect of proteins.
Naeem A; Fazili NA
Cell Biochem Biophys; 2011 Nov; 61(2):237-50. PubMed ID: 21573992
[TBL] [Abstract][Full Text] [Related]
16. Protein-misfolding diseases and chaperone-based therapeutic approaches.
Chaudhuri TK; Paul S
FEBS J; 2006 Apr; 273(7):1331-49. PubMed ID: 16689923
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic strategies for the treatment of protein-misfolding diseases.
Rochet JC
Expert Rev Mol Med; 2007 Jun; 9(17):1-34. PubMed ID: 17597554
[TBL] [Abstract][Full Text] [Related]
18. How a cell deals with abnormal proteins. Pathogenetic mechanisms in protein aggregation diseases.
Aigelsreiter A; Janig E; Stumptner C; Fuchsbichler A; Zatloukal K; Denk H
Pathobiology; 2007; 74(3):145-58. PubMed ID: 17643060
[TBL] [Abstract][Full Text] [Related]
19. Amyloid-beta fibrillogenesis: structural insight and therapeutic intervention.
Dasilva KA; Shaw JE; McLaurin J
Exp Neurol; 2010 Jun; 223(2):311-21. PubMed ID: 19744483
[TBL] [Abstract][Full Text] [Related]
20. Critical role of transglutaminase and other stress proteins during neurodegenerative processes.
Caccamo D; Currò M; Condello S; Ferlazzo N; Ientile R
Amino Acids; 2010 Feb; 38(2):653-8. PubMed ID: 19960212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
